echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > "First-in-class" Myasthenia Gravis Therapy Receives FDA Approval

    "First-in-class" Myasthenia Gravis Therapy Receives FDA Approval

    • Last Update: 2021-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, argenx announced that the US FDA approved the "first-in-class" therapy Vyvgart (efgartigimod alfa-fcab) for the treatment of anti-acetylcholine receptor (AChR) antibody-positive systemic myasthenia gravis (gMG) adult patients


    Myasthenia gravis is a rare chronic autoimmune disease


    Vyvgart is a "first-in-class" therapy targeting FcRn, designed to reduce pathogenic IgG antibodies and block the IgG recycling process


    This approval is based on the results of the global Phase 3 clinical trial ADAPT, which was published in The Lancet Neurology in July this year


    Reference materials:

    [1] argenx Announces US Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.